

November 13, 2019

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-003011-58 Novartis Protocol ID CACZ885M2301S2

A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP: An OGTT sub-study evaluating the effect of canakinumab on insulin secretion rate and other glucose control parameters following an oral glucose tolerance test in Type 2 diabetics

Trial CACZ885M2301S2 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.